{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:33:28Z","timestamp":1789914808816,"version":"4.0.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"9","content-domain":{"domain":["europeanneuropsychopharmacology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.euroneuro.2013.03.001","type":"journal-article","created":{"date-parts":[[2013,4,18]],"date-time":"2013-04-18T05:49:24Z","timestamp":1366264164000},"page":"1023-1033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: A meta-analysis and cochrane review of randomized controlled trials"],"prefix":"10.1016","volume":"23","author":[{"given":"Markus","family":"Dold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Gillies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2013.03.001_bib1","doi-asserted-by":"crossref","unstructured":"Bandelow, B., Zohar, J., Hollander, E., Kasper, S., M\u00f6ller, H.J., WFSBP task force on treatment guidelines for anxiety, obsessive-compulsive, and post-traumatic stress disorders, 2008. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders \u2013 first revision. World J. Biol. Psychiatry 9, 2248\u20132312","DOI":"10.1080\/15622970802465807"},{"key":"10.1016\/j.euroneuro.2013.03.001_bib2","first-page":"506","article-title":"Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia","volume":"149","author":"Barbee","year":"1992","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.03.001_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0735-6757(97)90119-4","article-title":"Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study","volume":"15","author":"Battaglia","year":"1997","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib4","series-title":"Comprehensive Meta-Analysis, Version 2","author":"Borenstein","year":"2006"},{"key":"10.1016\/j.euroneuro.2013.03.001_bib5","first-page":"CD000234","article-title":"Beta-blocker supplementation of standard drug treatment for schizophrenia","author":"Cheine","year":"2001","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/schbul\/17.2.217","article-title":"When symptoms persist: choosing among alternative somatic treatments for schizophrenia","volume":"17","author":"Christison","year":"1991","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1586\/14737175.9.1.55","article-title":"Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence?","volume":"9","author":"Citrome","year":"2009","journal-title":"Expert. Rev. Neurother"},{"key":"10.1016\/j.euroneuro.2013.03.001_bib8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.schres.2011.02.016","article-title":"Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behaviour","volume":"131","author":"Correll","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"Der-Simonian","year":"1986","journal-title":"Control Clin. Trials"},{"key":"10.1016\/j.euroneuro.2013.03.001_bib10","doi-asserted-by":"crossref","unstructured":"Dold, M., Li, C., Tardy, M., Khorsand, V., Gillies, D., Leucht, S., 2012. Benzodiazepines for schizophrenia. Cochrane Database Syst. Rev. CD006391.","DOI":"10.1002\/14651858.CD006391.pub2"},{"key":"10.1016\/j.euroneuro.2013.03.001_bib11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1176\/ajp.156.1.142","article-title":"Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior","volume":"156","author":"Dorevitch","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.03.001_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Br. Med. J."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","article-title":"Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009","volume":"138","author":"Gallego","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib14","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1176\/ajp.146.12.1598","article-title":"Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation","volume":"146","author":"Garza-Trevino","year":"1989","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.03.001_bib15","unstructured":"Gillies, D., Beck, A., McCloud, A., Rathbone, J., Gillies, D., 2005. Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis. Cochrane Database Syst. Rev. CD003079."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib17","first-page":"767","article-title":"The therapeutic effects of lorazepam in psychotic patients treated with haloperidol \u2013 a double blind study","volume":"14","author":"Guz","year":"1972","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib18","first-page":"104","article-title":"Combined drug treatment of newly hospitalized, acutely ill psychiatric patients","volume":"30","author":"Hanlon","year":"1969","journal-title":"Dis. Nerv. Syst."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib19","first-page":"171","article-title":"Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide and fluphenazine-imipramine","volume":"31","author":"Hanlon","year":"1970","journal-title":"Dis. Nerv. Syst."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib20","doi-asserted-by":"crossref","unstructured":"Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W.F., Thibaut, F., M\u00f6ller, H.J., WFSBP task force on treatment guidelines for schizophrenia, 2012. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part1: update on the acute treatment of schizophrenia and the management of treatment resistance. World J. Biol. Psychiatry 13, 318\u2013378.","DOI":"10.3109\/15622975.2012.696143"},{"key":"10.1016\/j.euroneuro.2013.03.001_bib21","doi-asserted-by":"crossref","unstructured":"Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W.F., Thibaut, F., M\u00f6ller, H.J., WFSBP task force on treatment guidelines for schizophrenia, 2013. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part2: update on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World.J. Biol. Psychiatry 14, 2\u201344","DOI":"10.3109\/15622975.2012.739708"},{"key":"10.1016\/j.euroneuro.2013.03.001_bib22","series-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0","author":"Higgins","year":"2011"},{"key":"10.1016\/j.euroneuro.2013.03.001_bib23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0010-440X(68)80059-8","article-title":"Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia","volume":"9","author":"Holden","year":"1968","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.03.001_bib24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative symptom scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/009127006600600203","article-title":"Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment: side effects and clinical laboratory findings","volume":"6","author":"Kurland","year":"1966","journal-title":"J. New Drugs"},{"key":"10.1016\/j.euroneuro.2013.03.001_bib26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/00004714-198912000-00003","article-title":"Successful clonazepam treatment of neuroleptic-induced akathisia in older adolescents and young adults: a double-blind, placebo-controlled study","volume":"9","author":"Kutcher","year":"1989","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib27","first-page":"1","article-title":"American psychiatric association, steering committee on practice guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.03.001_bib28","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.npp.1301147","article-title":"Linking the PANSS, BPRS, and CGI: clinical implications","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2013.03.001_bib29","first-page":"505","article-title":"Antipsychotic effect of diazepam when given in addition to neuroleptics in chronic psychotic patients \u2013 a double-blind clinical trial","volume":"26","author":"Lingjaerde","year":"1979","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib30","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1600-0447.1982.tb00855.x","article-title":"Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations. A multicentre double-blind, cross-over study","volume":"65","author":"Lingjaerde","year":"1982","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib31","first-page":"338","article-title":"The control study of injection of clonazepam into tinggong for auditory hallucination of schizophrenia","volume":"12","author":"Ma","year":"2006","journal-title":"J. Clin. Psychosom. Dis."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib32","first-page":"7533","article-title":"Anxiolytische Zusatzbehandlung bei den affektbetonten Schizophrenien. Ein Doppelblindversuch","volume":"29","author":"Marneros","year":"1979","journal-title":"Therapiewoche"},{"key":"10.1016\/j.euroneuro.2013.03.001_bib33","first-page":"551","article-title":"A double-blind comparison of alprazolam and placebo in the treatment of anxious schizophrenic outpatients","volume":"40","author":"Morphy","year":"1986","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib34","unstructured":"National Institute for Health and Clinical Excellence (NICE), 2009. Schizophrenia \u2013 core interventions in the treatment and management of schizophrenia in adults in primary and secondary care, [update 2009]."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib35","doi-asserted-by":"crossref","first-page":"790","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol. Rep."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib36","doi-asserted-by":"crossref","first-page":"e3150","DOI":"10.1371\/journal.pone.0003150","article-title":"Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use","volume":"3","author":"Pickar","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2013.03.001_bib37","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/00002826-199406000-00003","article-title":"A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia","volume":"17","author":"Pujalte","year":"1994","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib38","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJM199709183371202","article-title":"A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans affairs cooperative study group on clozapine in refractory schizophrenia","volume":"337","author":"Rosenheck","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.schres.2005.07.035","article-title":"Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials","volume":"80","author":"Rummel","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib40","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/schbul\/sbr004","article-title":"Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review","volume":"38","author":"Sommer","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1055\/s-2007-1014421","article-title":"Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis","volume":"25","author":"Stevens","year":"1992","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2013.03.001_bib42","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.schres.2011.09.016","article-title":"Treatment resistant schizophrenia and response to antipsychotics: a review","volume":"133","author":"Suzuki","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib43","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/archgenpsychiatry.2011.1532","article-title":"Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia","volume":"69","author":"Tiihonen","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.03.001_bib44","unstructured":"The Cochrance Collaboration, 2011. Software Review Manager (RevMan), Version 5.1.2."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib45","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/bmj.327.7417.708","article-title":"Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine","volume":"327","author":"TREC Collaborative Group","year":"2003","journal-title":"Br. Med. J."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib46","first-page":"143","article-title":"The control study of injection of clonazepam into t\u00b4ingkung for refractory auditory hallucination of schizophrenics","volume":"6","author":"Wang","year":"2000","journal-title":"J. Clin. Psychosom. Dis."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib47","first-page":"217","article-title":"An efficacy study of risperidone combined with clonazepam injection in the treatment of paranoid schizophrenia","volume":"13","author":"Wang","year":"2003","journal-title":"J. Clin. Psychol. Med."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib48","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1177\/0269881110379307","article-title":"British association for psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders","volume":"24","author":"Wilson","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.03.001_bib49","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1176\/ajp.148.6.714","article-title":"Benzodiazepines in the treatment of schizophrenia: a review and reappraisal","volume":"148","author":"Wolkowitz","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.03.001_bib50","first-page":"244","article-title":"Clinical observation on the effect of risperidone combined with BZD on schizophrenia","volume":"7","author":"Xuan","year":"2007","journal-title":"China Trop. Med."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X13000722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X13000722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:44:27Z","timestamp":1688172267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X13000722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0924977X13000722"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2013.03.001","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718002189.793477492","asserted-by":"object"}]},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: A meta-analysis and cochrane review of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2013.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}